POST-TEST

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Commonly mutated genes in small cell lung cancer include ___________.
   a. TP53
   b. PTEN
   c. RB1
d. All of the above

2. The SWOG-S1400 biomarker-driven Lung Master Protocol study evaluating second-line therapy for squamous cell lung cancer has as its primary endpoint(s) ___________.
   a. Progression-free survival
   b. Overall survival
c. Both a and b

3. A combined analysis of the LUX-Lung 3 and LUX-Lung 6 Phase III trials of first-line therapy failed to demonstrate an overall survival benefit with afatinib versus chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with EGFR del(19) mutations.
   a. True
   b. False

4. Adverse events commonly associated with the EGFR inhibitor CO-1686 include ___________.
   a. Nausea
   b. Hyperglycemia
c. Thrombocytopenia
d. Both a and b
e. All of the above

5. The ongoing Phase III ALEX study is comparing alectinib to crizotinib for patients with ALK-positive advanced NSCLC.
   a. True
   b. False

6. The ongoing ARCTIC and KEYNOTE-021 studies are currently evaluating ___________ with other agents versus standard therapy for patients with lung cancer.
   a. Anti-PD-L1 and anti-PD-1 antibodies
   b. EGFR inhibitors
c. Neither a nor b

7. The ECOG-E5508 trial of maintenance therapy options for advanced NSCLC is randomly assigning patients to maintenance with bevacizumab, pemetrexed or ___________.
   a. Erlotinib
   b. Pemetrexed/bevacizumab
c. Neither a nor b

8. The Phase III SQUIRE trial demonstrated a statistically significant overall survival benefit with the addition of ___________ to gemcitabine/cisplatin as first-line therapy for advanced squamous cell NSCLC.
   a. Ramucirumab
   b. Afatinib
c. Necitumumab
d. Crizotinib

9. The MARS trial demonstrated no difference in survival among patients with mesothelioma who received preoperative chemotherapy, extrapleural pneumonectomy and radiation therapy compared to preoperative chemotherapy alone.
   a. True
   b. False

10. ___________ blockade is currently being investigated as a competing strategy compared to cytotoxic/targeted therapy for mesothelioma.
    a. Anti-PD-1/PD-L1
    b. CTLA4
c. Both a and b
d. Neither a nor b